25N-NBOMe

From PsychonautWiki
(Redirected from 25nnbome)
Jump to: navigation, search

Skull and crossbones darktextred2.png

Many members of the NBOMe series have been linked with numerous overdoses and fatalities.[1][2][3]

It is strongly discouraged to take higher doses of these substances or to insufflate (snort) them. Please see this section for more details.

Summary sheet: 25N-NBOMe
25N-NBOMe
25N-NBOMe.svg
Chemical Nomenclature
Common names 25N-NBOMe
Systematic name 2-(2,5-dimethoxy-4-nitrophenyl)-N-(2-methoxybenzyl)ethanamine
Class Membership
Psychoactive class Psychedelic
Chemical class Phenethylamine
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.





Sublingual
Dosage
Threshold < 100 µg
Light 100 - 300 µg
Common 300 - 800 µg
Strong 800 - 1300 μg
Heavy The NBOMe series can be fatal at heavy doses.[4][5][6]
Duration
Total 5 - 10 hours
Onset 45 - 75 minutes
Peak 2 - 3 hours
Offset 2 - 3 hours
After effects 5 - 10 hours
Insufflated
Dosage
Heavy The NBOMe series can be fatal when insufflated.[4][5][6] It is strongly discouraged.
Duration
Total 4 - 8 hours






DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

25N-NBOMe (also known as 2C-N-NBOMe and N-Bomb, although this term is used broadly to refer to the entire 25x-NBOMe family) is a novel psychedelic substance of the phenethylamine chemical class that produces stimulating psychedelic effects when administered.

The name 25N-NBOMe, which short-hand for 2C-N-NBOMe, is a derivative of the phenethylamine psychedelic 2C-N. It was discovered in 2004 by Ralf Heim at the Free University of Berlin[7] and subsequently investigated by a team at Purdue University led by David E. Nichols.[8]

25N-NBOMe has a notably shorter duration than the rest of the 25x-NBOMe series with a total duration of 6 hours and a peak duration of 2 hours.[9] It is moderately active at a dose of one milligram, and two milligrams provide a strong/heavy trip.[10] This substance is considerably less potent when compared to the more popular NBOMe compunds such as 25B-NBOMe, 25I-NBOMe and 25C-NBOMe, all which produce strong experiences at doses above 1mg.[citation needed] Compounds of the NBOMe family are not orally active and should be administered sublingually by placing and holding it into one's mouth and allowing it to absorb over a period of 15-25 minutes.

This substance had no history of human use before being sold online as a designer drug in 2010.[citation needed] Extremely little is known about the pharmacological properties, metabolism, and toxicity of 25N-NBOMe in humans, and many members of the 25x-NBOMe series have been associated with deaths and hospitalizations. Along with its highly sensitive dose-response and unpredictable effects, many reports also suggest that this substance may be overly difficult to use safely. Therefore it is highly advised to approach this poorly understood psychedelic substance with the proper amount of precaution and harm reduction practices if using it.

Chemistry

25N-NBOMe or 2C-N-NBOMe is a serotonergic N-benzyl derivative of the substituted phenethylamine psychedelic known as 2C-N. 25N-NBOMe is a substituted phenethylamine with methoxy groups CH3O- attached to carbons R2 and R5 as well as a nitro group NO2- attached to carbon R4. It differs from 2C-N structurally through a substitution on the amine (NH2) with a 2-methoxybenzyl (BOMe) group as shown in the image to the right. 25N-NBOMe shares this 2-methoxybenzyl substitution with other chemicals of the NBOMe family. This NBOMe addition contains a methoxy ether CH3O- bound to a benzene ring at R2.

Pharmacology

Further information: Serotonergic psychedelic

25N-NBOMe likely has efficacy at the 5-HT2A receptor where it is assumed to act as a partial agonist. However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.

There is insufficient scientific research to determine this compound's true nature as the pharmacological properties of 25N-NBOMe have not been described in the scientific literature, but only in anecdotal reports.[11]

Subjective effects

The effects listed below are based upon the subjective effects index and personal experiences of PsychonautWiki contributors. These effects should be taken with a grain of salt and will rarely (if ever) occur all at once, but heavier doses will increase the chances of inducing a full range of effects. Likewise, adverse effects become much more likely on higher doses and may include serious injury or death.

Physical effects
Child.svg

Visual effects
Eye.svg

Cognitive effects
User.svg

Multi-sensory effects
Gears.svg

Transpersonal effects
Infinity4.svg


Toxicity and harm potential

The toxicity and long-term health effects of recreational 25N-NBOMe use have not been studied in any scientific context and the exact toxic dosage is unknown. This is because 25N-NBOMe is a research chemical with very little history of human usage. Anecdotal evidence from people within the psychonaut community who have tried 25N-NBOMe suggests that there are no negative health effects attributed to simply trying the drug by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed).

Users should be very careful and consider that ingesting 2mg+ of NBOMe series chemicals have proven fatal in some cases. Although there are no reported deaths caused by 25N-NBOMe at this time, it is a rare research chemical with very little history of human usage and is therefore potentially fatal at heavy dosages.

It is strongly recommended that one use harm reduction practices when using this drug.

Tolerance and addiction potential

25N-NBOMe is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating.

Tolerance to the effects of 25N-NBOMe are built almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). 25N-NBOMe presents cross-tolerance with all psychedelics, meaning that after the consumption of 25N-NBOMe all psychedelics will have a reduced effect.

Dangerous interactions

Although many psychoactive substances are safe to use on their own, they can quickly become dangerous or even life-threatening when combined with other substances. The following lists some known dangerous combinations, but may not include all of them. A combination that appears to be safe in low doses can still increase the risk of injury or death. Independent research should always be conducted to ensure that a combination of two or more substances is safe to consume.

Legality

Handcuffs-300px.png

This legality section is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

  • Austria: 25N-NBOMe is illegal to possess, produce and sell under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich).[citation needed]
  • Brazil - Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.[13]
  • Germany - Possession, production and sale is illegal.[14]
  • Latvia: 25N-NBOMe is a Schedule I controlled substance.[15]
  • United Kingdom - 25N-NBOMe is a Class A drug in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause.[16]
  • United States: 25N-NBOMe is unscheduled in the United States. It may be considered an analogue of 2C-N (which is a Schedule I drug under the Controlled Substances Act). As such, the sale for human consumption or the use for illicit non-medical or industrial intents and purposes could be prosecuted as crimes under the Federal Analogue Act.

See also

External links

References

  1. 25I-NBOMe (2C-I-NBOMe) Fatalities / Deaths by Erowid | https://www.erowid.org/chemicals/2ci_nbome/2ci_nbome_death.shtml
  2. 25C-NBOMe (2C-C-NBOMe) Fatalities / Deaths by Erowid | https://www.erowid.org/chemicals/2cc_nbome/2cc_nbome_death.shtml
  3. Other or Unknown NBOMe Compound Fatalities / Deaths by Erowid | https://www.erowid.org/chemicals/nbome/nbome_death.shtml
  4. 4.0 4.1 25I-NBOMe (2C-I-NBOMe) Fatalities / Deaths by Erowid | https://www.erowid.org/chemicals/2ci_nbome/2ci_nbome_death.shtml
  5. 5.0 5.1 25C-NBOMe (2C-C-NBOMe) Fatalities / Deaths by Erowid | https://www.erowid.org/chemicals/2cc_nbome/2cc_nbome_death.shtml
  6. 6.0 6.1 Other or Unknown NBOMe Compound Fatalities / Deaths by Erowid | https://www.erowid.org/chemicals/nbome/nbome_death.shtml
  7. Ralf Heim PhD. (2010-02-28) "Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2-Methoxybenzyl-Partialstruktur. Entwicklung eines neuen Struktur-Wirkungskonzepts." | http://www.diss.fu-berlin.de/diss/receive/FUDISS_thesis_000000001221 (in German). diss.fu-berlin.de. Retrieved 2013-05-10.
  8. Michael Robert Braden PhD. (2007). "Towards a biophysical understanding of hallucinogen action." | http://proquest.umi.com/pqdlink?Ver=1&Exp=01-23-2014&FMT=7&DID=1417800971&RQT=309&attempt=1&cfc=1 Purdue University. Retrieved 2012-08-08.
  9. http://www.bluelight.org/vb/threads/539694-The-Big-amp-Dandy-25N-NBOMe-Thread
  10. https://www.drugs-forum.com/forum/showthread.php?t=249067
  11. The Big & Dandy 25N-NBOMe Thread | http://www.bluelight.org/vb/threads/539694-The-Big-amp-Dandy-25N-NBOMe-Thread
  12. Talaie, H., Panahandeh, R., Fayaznouri, M. R., Asadi, Z., & Abdollahi, M. (2009). Dose-independent occurrence of seizure with tramadol. Journal of medical toxicology, 5(2), 63-67. doi:10.1007/BF03161089
  13. http://portal.anvisa.gov.br/documents/10181/3115436/%281%29RDC_130_2016_.pdf/fc7ea407-3ff5-4fc1-bcfe-2f37504d28b7
  14. BtMG Anlage I | https://www.gesetze-im-internet.de/btmg_1981/anlage_i.html
  15. Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem (2,5-Dimetoksifeniletānamīni) | http://likumi.lv/doc.php?id=121086
  16. United Kingdom. (2014). Misuse of Drugs Act 1971 (S.I. 2014/1106). London: The Stationery Office Limited. Retrieved July 5, 2017, from http://www.legislation.gov.uk/uksi/2014/1106/made